Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Noden gets worldwide license to Novartis hypertension drugs

Executive Summary

Specialty pharmaceutical company Noden Pharma DAC licensed exclusive worldwide manufacturing, marketing, and sales rights to Novartis AG's hypertension drug Rasilez (aliskiren). The deal also includes Rasilez HCT, a fixed-dose tablet combination of aliskiren and hydrochlorothiazide (HCT).
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Marketing (Licensing)
    • Reverse Licensing

Related Companies